Back to Global FoodMate |Add To Favorites | Browse
regular members

Radiator

服饰,零食

Monday,Sep 30, 2024
Product category
  • No categories temporary
Search
 
Certifications
  • not upload temporary
Friendly link
  • no link temporary
Current Position:Home » Our News » What are pharmaceutical intermediates?
Our News
What are pharmaceutical intermediates?
Posted:Jun 09, 2022        Views:305        Back to List
 Pharmaceutical intermediates are chemical compounds widely used in manufacturing various types of drugs in bulk quantity and also used for research and development by Pharmaceutical and biopharma companies.

Pharmaceutical Intermediates Market - about the Report

Pharmaceutical intermediates are used as raw materials during the manufacture of bulk drugs. Leading biopharmaceutical and pharmaceutical manufacturing companies are focusing on improving their product footprint globally. These companies are focusing on strengthening their product reach in different countries across the world through various distribution channels. Growth outlook therefore remains positive for pharmaceutical intermediates market as companies continue focusing on enhancing the capacities of their manufacturing plants in various countries of the world.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors fuelling demand for pharmaceutical intermediates. The report tracks the global sales of pharmaceutical intermediates in 20+ high-growth markets, along with analyzing the impact COVID-19 has on the pharmaceutical industry in general and the market in particular.

 

D-Cycloserine Intermediates

Human brain imaging studies indicate that the medial prefrontal cortex activity can predict more than 80% of the variance of chronic back pain intensity. Therefore, the investigators have hypothesized that modulation of brain activity at this site should result in analgesia. D-cycloserine Intermediates have been shown to potentiate conditioned fear extinction. Based on this the investigators hypothesize that chronic neuropathic pain (back pain with radiculopathy) is partially mediated or potentiated by decreased ability to extinguish the pain memory, which the investigators hypothesize to be mediated through reward/aversion brain circuitry, and specifically through the medial prefrontal cortex. They have tested this idea in pre-clinical studies and demonstrated that rats with neuropathic pain show analgesia over the long term when treated with D-cycloserine. In humans with chronic back pain, the investigators hypothesize that D-cycloserine will enhance the extinction of back pain which in turn should result in reduced emotional relevance of the pain, that is reduced suffering. It is quite possible that the overall intensity of the back pain will be unaffected, however, the associated suffering will be significantly attenuated.